An image of a person is shown with attention drawn to fat accumulated in his liver, a feature of the liver disease non-alcoholic steatohepatitis (NASH). Next to the person is a blue circle with an image of a liver with kisspeptin hormone receptors depicted on the surface of the liver and arrows pointing downward to indicate a decrease in fatty liver and NASH. 

liver-sex-hormone

An image of a person is shown with attention drawn to fat accumulated in their liver, a feature of the liver disease, non-alcoholic steatohepatitis (NASH). Next to the person is a blue circle with an image of a liver inside of it with kisspeptin hormone receptors depicted on the surface of the liver and arrows pointing downward to indicate a decrease in fatty liver and NASH. 

Rutgers University scientists who investigated the role of kisspeptin in liver disease stand together in a laboratory.

liver-group

Scientists found that the Kisspeptin hormone activates enzymes that stop lipid formation in the mouse liver, suggesting that it has potential as a drug target for treating non-alcoholic fatty liver disease.

A sex hormone may help reverse liver damage

News

Anthony Samir is an expert in ultrasound imaging for liver disease at Harvard Medical School.

Stephen Williams is the Chief Medical Officer at SomaLogic.

08242021-somalogic19ga

istock-1322425857-1800x900

Sophie Cazanave is a NASH researcher at Glympse Bio.

21017-glympse-websitestillsv3-proteaseinbloodvial

Wendy Winkler is the Chief Scientific Officer at Glympse Bio.

A close up view of a vial of blood is pictured with peptides of different length floating in it. These peptides may be indicative of fatty liver disease.

wendy

SomaLogic scientists work in the lab to develop protein-based diagnostic tests for NASH.

Through academic, industry, and governmental partnerships, scientists validate and develop non-invasive diagnostics for non-alcoholic fatty liver disease. These tests are set to replace the invasive and risky gold standard: liver biopsy.

Goodbye biopsies, non-invasive diagnostics for fatty liver disease are here

Median Technologies teams up with UC San Diego on diagnosing liver fibrosis severity in NASH patients

Grading non-alcoholic steatohepatitis

Articles

iBiopsy study shows promise in diagnosing severity of disease in patients

AI is put to work on NASH biomarkers

Transcriptome sequencing of patients with liver disease reveals gene expression changes that could help to track disease severity and progression

A new angle on NAFLD

Owlstone study pinpoints limonene for early diagnosis of NASH and NAFLD

A promising biomarker for diagnosing liver disease

june-2025-cover

June 2025

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.

integraebook

A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.

integra-logo-transparent-1

INTEGRA Biosciences

From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.

How to become a PCR pro

Ebooks

Tackling mycoplasma contamination in biotherapeutic production

80760-webinar-banners-july-23-kr1800x900-plain-istock

Thermo Fisher Scientific

DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.

Webinars

Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.

untitled-2

primary-lockup-p-500-1-64e0fe115-1

Salad Technologies

Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.

NAFLD